



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board Health First Colorado, Colorado's Medicaid program

MEETING AGENDA

AUGUST 12, 2025

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

DUR Board Members

Brian Jackson, MD, MA (Chair)
Liza Claus, PharmD (Vice Chair)
Marshal Ash, DO
Todd Brubaker, DO
Stephanie Cho, PharmD
Shilpa Klocke, PharmD
Kenneth MacIntyre, DO
Ingrid Pan, PharmD
Mary Shefchyk, MBA

DUR Team

Jeffrey Taylor, PharmD (HCPF)
Veronia Garcia, PharmD (HCPF)
Rachele Poissant, PharmD (HCPF)
Julia Rawlings, PharmD (CO-DUR)
Robert L Page II, PharmD, MSPH (CO-DUR)
Gina Moore, PharmD, MBA (CO-DUR)
Heather Anderson, PhD (CO-DUR)
Garth Wright, MPH (CO-DUR)
Mouna Dardouri, PharmD, MPH, PhD student (CO-DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the May 6, 2025 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest
Presentations:
 - Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
 - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting
7. Clinical Updates and General Orders
 - a. FDA Safety Communications
 - b. FDA New Approvals Report
 - c. Quarterly Module Summary
 - d. Retrospective DUR Reports
 - e. Quarterly Drug Utilization Reports

8. New Business (Open for public testimony and DUR Board review)

A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Antipsychotics, Long Acting Injectable
- Androgenic Agents
 - Topical
 - Injectable
 - Oral
- Contraceptives, Topical
- Bone Resorption Suppression and Related Agents
- Diabetes Management Classes, Non-Insulin
 - DPP-4 Inhibitors
 - GLP-1 Receptor Analogues
 - SGLT-2 Inhibitors
- Growth Hormones
- Benign Prostatic Hyperplasia (BPH) Agents

Mass review drug classes*

- Diabetes Management Classes - Insulins
 - Rapid
 - Short
 - Intermediate
 - Long Acting
 - Mixtures
 - Concentrated
- Diabetes Management Classes, Non-Insulins
 - Amylin
 - Biguanides
 - Meglitinides
 - Thiazolidinediones (TZDs)
 - Combinations
- Estrogen Agents
 - Oral/Transdermal
 - Injectable
- Glucagon, Self-Administered
- Phosphate Binders
- Prenatal Vitamins/Minerals
- Antihyperuricemics
- Overactive Bladder Agents

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

B. Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDL> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization.)

- VYKAT XR (diazoxide choline)
- KHINDIVI (hydrocortisone)
- ALKINDI SPRINKLE (hydrocortisone)
- VANRAFIA (atrasentan)
- IMAAVY (nipocalimab)
- ZELSUVMI (berdazimer)
- PCSK9 Inhibitors:
 - EVKEEZA (evinacumab)
 - PRALUENT (alirocumab)
 - REPATHA (evolocumab)

9. Adjournment

Next meeting date: Tuesday, November 4, 2025

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.